This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Alison Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Chris Barber
- Crina Heghes
- Dave Yeo
- David Ponting
- Grace Kocks
- Hazel Gardiner
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Michael Burns
- Nik Marchetti
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rob Foster
- Scott McDonald
- Susanne Stalford
Filter by Product
As a member-based organisation, anticipating and supporting the needs of our members is critical.
31 July 2020
For many years the Carcinogenic Potency Database (CPDB)1, created by Lois Gold and her team, was an important source of long-term carcinogenicity study data. However, as the database had stopped being updated from 2007, Lhasa moved to safeguard the data by providing ongoing access through a freely available interface; the Lhasa Carcinogenicity Database (LCDB)2. The LCDB was released in 2016 and has since been updated with additional data from the National Toxicology Program (NTP)3, increasing the data set to 7,745 studies covering 1,726 chemical substances. A recent update has also facilitated greater ease of access by enabling substructure and similarity-based structure queries.
08 December 2020
Artificial Intelligence (AI) has become a powerful force within the pharmaceutical industry, catalysed by the challenging lengthy and costly drug development process. To maximize the impact of AI, it is critical to have access to enough good quality data to allow machine learning algorithms to extract relevant knowledge and produce valuable models.
21 May 2020
The world of work is changing. My goodness is that an understatement! Never have I truly felt that we are working in what is described as a VUCA (volatile, uncertain, complex and ambiguous) world as much as I do right now.
18 January 2021
Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.
17 February 2021
The speed by which models for toxicity prediction can be built and the accuracy with which they can make predictions, have both improved greatly in recent years as a result of advances in technology, mechanistic understanding and access to data.
21 May 2020
In his blog “Human review of in silico predictions of toxicity”, Principal Scientist, Alex Cayley, outlined the reasons why expert review is essential when using in silico tools to assess toxicity, particularly in the ICH M7 use case where expert review of two complementary in silico systems is required .
In this post we discuss how consideration of the user’s journey led to Lhasa tackling the ICH M7 use case with a brand-new automated workflow, now available to Derek and Sarah users in Nexus 2.3. I’ll also show some worked examples of results from the new system.
16 June 2020
The saying goes, “It takes a village to raise a child”. This sentiment can be translated to the work we do at Lhasa Limited, particularly to the work which we put into building Adverse Outcome Pathways (AOPs). To echo the sentiment in Chris Barber’s previous blog post, The challenge of building QSAR models; it is easy to build an AOP, harder to build a useful AOP, and as for building an AOP you can trust? It takes a team.
Read about how we are building adverse outcome pathways (AOPs) at Lhasa in this blog post written by Dr. Susanne Stalford, Senior Scientist at Lhasa.
30 September 2020
The global pandemic has undoubtedly had a huge impact on many companies in 2020, Lhasa is no exception.
14 January 2021
Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.
Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.
However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.
29 October 2020
Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
25 June 2020
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.
13 July 2020
Anax started at Lhasa in September (remotely from Brazil) two months later, Alison checks in to see how things are going. Learn about Anax’s passion for toxicology, career to date, biggest inspiration, plans for his new role at Lhasa and last but not least, where we should all visit in Brazil, in this Q&A session – enjoy!
30 November 2020
There is no perfect formula when it comes to trying to organise any kind of work trip. Normally, you have to engage through a series of mental gymnastics to try and balance semi-quantifiable concepts such as ‘return on investment’ and ‘value’.
Let’s take ‘value’ for instance. Is the value of the trip based on a new sale? The time spent out of the office? Establishing a personal contact to secure existing business? Ensuring that the product that you’re supporting is used and understood to the maximum capacity?
Now balance that with travelling halfway across the planet, rather than a quick hop on the Eurostar.
Read more about our trip to India earlier this year.
15 June 2020
AOPs have the potential to be very powerful for the contextualisation of alternative assays and consequently for the management of alternative testing strategies. Read about what Lhasa is doing in this area in this blog piece written by Alun Myden, Senior Scientist at Lhasa.
03 July 2020
Building QSAR models is easy. Building useful QSAR models is harder. Building QSAR models you can trust – well that can be really challenging – and this is where a lot of Lhasa’s effort is dedicated – creating models that can be used with confidence to make big decisions – such as those made during a regulatory submission that can protect human safety through exposure of a compound or its impurities!
19 May 2020
Throughout the history of science, progression has relied upon the generation of new knowledge and then building on that knowledge in order to gain even greater insight. In order to progress, this knowledge needs to be shared as widely as possible.
26 June 2020
An award honouring the scientific contributions and memory of Dr. Richard Williams, has been set up to support early career investigators within industry. Supported by the Industrial Genotoxicology Group (IGG), The Richard Williams Memorial Award will sponsor one individual a year to attend and present at the United Kingdom Environmental Mutagen Society (UKEMS) meeting.
26 July 2020
One of the most important ingredients for an effective team is trust, and a critical phase of team building is starting to develop that sense of trust – to be strong has to be earnt and regularly reinforced; it is rarely simply given! The same is true when using in silico models and by mirroring the natural approaches – the intuitive tests that we apply either consciously or subconsciously - we can understand how and when a model can be effectively used.
15 May 2020